VSTM U.S.: Nasdaq

    Verastem Inc.

    Back To Top
    Last Updated: Jun 23, 2021 11:59 a.m. EDT Real time quote

    $ 4.1200

    -0.1600 -3.74%
    Previous Close
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 2.2M 65 Day Avg: 2.86M
    77% vs Avg
    4.0400 Day Range 4.3300
    1.0800 52 Week Range 4.9350

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    VSTM Overview


    5 Day
    • -11.59%
    1 Month
    • 2.49%
    3 Month
    • 78.35%
    • 93.43%
    1 Year
    • 122.70%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 3 Full Ratings

    Recent News

    • eLesor
    • Dow Jones

    Verastem Shares Rise 8% After FDA Breakthrough Designation for Cancer Treatment

    Verastem downgraded to market perform from outperform at Raymond James

    Verastem stock price target cut to $6 from $12 at Raymond James

    Verastem's stock was up 3.3% prior to trading halt

    Verastem's stock halted for news pending

    Verastem started at buy with $14 stock price target at Seaport Global

    Stocks to watch Thursday: Green Mountain, Merck

    Read full story

    A busy IPO year as Facebook buzz builds

    Verastem climbs in early post-IPO trading

    • Other News
    • Press Releases

    2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin

    on Motley Fool

    3 Monster Growth Stocks That Could Reach New Highs

    on TipRanks.com

    Verastem (VSTM) Enters Overbought Territory

    on Zacks.com

    Why Verastem Stock Is Crushing It Today

    on Motley Fool

    Verastem (VSTM) Receives a Buy from H.C. Wainwright

    on SmarterAnalyst

    H.C. Wainwright Reaffirms Their Buy Rating on Verastem (VSTM)

    on SmarterAnalyst

    Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer

    on Zacks.com

    Verastem (VSTM) Jumps: Stock Rises 7.1%

    on Zacks.com

    Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?

    on Zacks.com

    Verastem (VSTM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    on Zacks.com

    Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?

    on Zacks.com

    Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?

    on Zacks.com

    Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?

    on Zacks.com

    Earnings Estimates Moving Higher for Verastem (VSTM): Time to Buy?

    on Zacks.com

    Has Verastem (VSTM) Outpaced Other Medical Stocks This Year?

    on Zacks.com

    Verastem Sees Hammer Chart Pattern: Time to Buy?

    on Zacks.com

    Verastem, Inc. (VSTM) Shares March Higher, Can It Continue?

    on Zacks.com

    Steven Cohen Renews His Interest in Verastem

    on GuruFocus.com

    Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up

    on Zacks.com

    Implied Volatility Surging for Verastem (VSTM) Stock Options

    on Zacks.com

    Verastem Inc.

    Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.


    Name Chg % Market Cap
    Pfizer Inc. -1.24% $221.72B
    Laboratory Corp. of America Holdings -0.51% $26.1B
    GlaxoSmithKline PLC ADR 1.93% $97.13B
    Competitor Data Provided ByCapital Cube Logo